Cover Image

Off-Label Use of Dalbavancin for Sequential Treatment of Spondylodiscitis by Methicillin-Resistant <i>Staphylococcus aureus</i>: A Retrospective Single-Centre Experience

<b>Background:</b> Our aim was to describe the clinical outcome and safety of the sequential treatment with off-label dalbavancin in patients with spondylodiscitis that is caused by methicillin-resistant <i>Staphylococcus aureus</i> (MRSA). <b>Methods</b>: We retr...

Full description

Saved in:

Bibliographic Details
Main Authors:	Maria Mazzitelli (Author), Milo Gatti (Author), Vincenzo Scaglione (Author), Daniele Mengato (Author), Marco Trevenzoli (Author), Andrea Sattin (Author), Federico Pea (Author), Anna Maria Cattelan (Author)
Format:	Book
Published:	MDPI AG, 2022-10-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Evaluating the Use of Dalbavancin for Off-Label Indications
by: Katherine Taylor, et al.
Published: (2022)

Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization
by: Simonetti O, et al.
Published: (2021)

Population Pharmacokinetic and Pharmacodynamic Analysis of Dalbavancin for Long-Term Treatment of Subacute and/or Chronic Infectious Diseases: The Major Role of Therapeutic Drug Monitoring
by: Pier Giorgio Cojutti, et al.
Published: (2022)

Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and <i>Enterococcus faecium</i>
by: Robert E. Weber, et al.
Published: (2021)

Fast and Simple Liquid Chromatography-Isotope Dilution Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Dalbavancin in Long-Term Treatment of Subacute and/or Chronic Infections
by: Rossella Barone, et al.
Published: (2023)

Pharmacokinetic/pharmacodynamic issues for optimizing treatment with beta-lactams of Gram-negative infections in critically ill orthotopic liver transplant recipients: a comprehensive review
by: Milo Gatti, et al.
Published: (2024)

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i> in Critically Ill Adult Patients
by: Milo Gatti, et al.
Published: (2021)

Long-Term Suppressive Therapeutic-Drug-Monitoring-Guided Dalbavancin Therapy for Cardiovascular Prosthetic Infections
by: Altea Gallerani, et al.
Published: (2023)

In Vitro Activities of Ceftobiprole, Dalbavancin, Tedizolid and Comparators against Clinical Isolates of Methicillin-Resistant <i>Staphylococcus aureus</i> Associated with Skin and Soft Tissue Infections
by: Sofia Maraki, et al.
Published: (2023)

Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs
by: Gatti M, et al.
Published: (2021)

Pharmacokinetic/Pharmacodynamic Analysis of Continuous-Infusion Fosfomycin in Combination with Extended-Infusion Cefiderocol or Continuous-Infusion Ceftazidime-Avibactam in a Case Series of Difficult-to-Treat Resistant <i>Pseudomonas aeruginosa</i> Bloodstream Infections and/or Hospital-Acquired Pneumonia
by: Milo Gatti, et al.
Published: (2022)

Pyogenic spondylodiscitis: An overview
by: G.S. Skaf, et al.
Published: (2010)

Could an Optimized Joint Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin-Tazobactam Be a Valuable Innovative Approach for Maximizing the Effectiveness of Monotherapy Even in the Treatment of Critically Ill Patients with Documented Extended-Spectrum Beta-Lactamase-Producing <i>Enterobacterales</i> Bloodstream Infections and/or Ventilator-Associated Pneumonia?
by: Milo Gatti, et al.
Published: (2023)

Microbiological Profiles of Patients with Spondylodiscitis
by: Frank Sebastian Fröschen, et al.
Published: (2024)

Brucellar spondylodiscitis mimicking tuberculosis
by: Eshani Dewan, et al.
Published: (2015)

In Vitro Activity of Dalbavancin against Refractory Multidrug-Resistant (MDR) <i>Staphylococcus aureus</i> Isolates
by: Dafne Bongiorno, et al.
Published: (2020)

Spontaneous methicillin-sensitive Staphylococcus aureus spondylodiscitis-Short course antibiotic therapy may be adequate: Evidence from a single centre cohort
by: Thomas Locke, et al.
Published: (2014)

Off-label drugs use in pediatric palliative care
by: Lucia De Zen, et al.
Published: (2018)

Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
by: Pier Giorgio Cojutti, et al.
Published: (2022)

Spondylodiscitis and an aortic aneurysm due to <it>Campylobacter coli</it>
by: Bournet Béatrice, et al.
Published: (2010)

Methicillin-Resistant and Methicillin-Susceptible <i>Staphylococcus</i> from Vervet Monkeys (<i>Chlorocebus sabaeus</i>) in Saint Kitts
by: Andreas Hoefer, et al.
Published: (2021)

Off-label drug in the newborn
by: Laura Cuzzolin
Published: (2014)

Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of <i>Staphylococcus aureus</i> in a Pharmacokinetic/Pharmacodynamic Model
by: Jacinda C. Abdul-Mutakabbir, et al.
Published: (2020)

Typhoid spondylodiscitis mimicking tuberculosis in a teenage girl
by: Barnini Banerjee, et al.
Published: (2018)

Spondylodiscitis as the only clinical manifestation of the onset of psoriatic spondyloarthritis
by: V. Bruzzese
Published: (2011)

Spondylodiscitis Mimicking Benign Tumors in Ankylosing Spondylitis Patient
by: Fatih Bağcıer, et al.
Published: (2016)

Biologics in dermatology: Off-label indications
by: Debdeep Mitra, et al.
Published: (2020)

Off-label uses of retinoids in dermatology
by: Wei Li, et al.
Published: (2012)

Challenges on off label medicine use
by: Marisa Lima Carvalho
Published: (2016)

PRESCRIÇÃO DE MEDICAMENTOS OFF-LABEL
by: Ana Escoval, et al.
Published: (2011)

List of diseases with off-label treatment
by: article Editorial
Published: (2022)

Off-label prescription of drugs at hospital
by: Vicente Arocas Casañ, et al.
Published: (2016)

The journey of canakinumab; on- and off-label indications
by: Daniela Marotto, et al.
Published: (2019)

Off-label pediatric medicines in Spain
by: Roi Piñeiro Pérez, et al.
Published: (2021)

Off-label and unlicensed drugs in neonatology
by: Segundo Rite-Gracia, et al.
Published: (2021)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China
by: Weilan Wang, et al.
Published: (2013)

Off-Label and Off-NCCN Guidelines Uses of Antineoplastic Drugs in China.
by: Weilan Wang, et al.
Published: (2013)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
by: Elisa Molinelli, et al.
Published: (2022)

Dalbavancin in the treatment of skin and soft tissues infection
by: Ana Candela Fajardo, et al.
Published: (2017)

Infectious spondylodiscitis and kyphosis correction in an infant: a case report
by: Sara Romano, et al.
Published: (2021)